AnaptysBio, Inc. reported positive results on June 3, 2025, from its Phase 2b clinical trial on rosnilimab for rheumatoid arthritis, showing significant efficacy and safety in a 424-patient study over six months. The results indicate durable responses and are promising for moderate-to-severe cases, which could boost their market position.